| Nucleus Basalis of Meynert Cholinergic Neurons | |
|---|---|
| Basal Forebrain Cholinergic System | |
| Allen Atlas ID | Mouse: GSN0002005 |
| Lineage | Neuron > GABAergic > Basal Forebrain Cholinergic |
| Markers | ChAT, p75NTR (NGFR), SLC18A3 (VAChT), NGF, BDNF |
| Brain Regions | Substantia innominata, Horizontal Diagonal Band, Vertical Diagonal Band |
| Disease Vulnerability | Alzheimer's Disease, Dementia with Lewy Bodies, Parkinson's Disease |
Nucleus Basalis Meynert Cholinergic Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Nucleus Basalis of Meynert (NBM) is the largest cholinergic nuclei in the basal forebrain and serves as the primary source of cortical acetylcholine. These projection neurons are essential for cortical activation, attention, learning, and memory consolidation [1][2]. The NBM is severely affected in Alzheimer's disease (AD), where degeneration of these cholinergic neurons underlies the characteristic cognitive decline and represents a key therapeutic target for symptomatic treatment [3][4].
The NBM is part of the basal forebrain cholinergic system (BFCS), which includes the medial septum (MS), vertical and horizontal diagonal bands of Broca (VDB/HDB), and the nucleus basalis of Meynert proper. Together, these nuclei provide the majority of cholinergic innervation to the hippocampus and neocortex [5].
The NBM is located in the substantia innominata of the basal forebrain:
NBM cholinergic neurons receive inputs from:
Cortical projection patterns:
| Target Region | Function | Cholinergic Modulation |
|---|---|---|
| Prefrontal Cortex | Executive function, working memory | Enhances signal-to-noise ratio [13] |
| Parietal Cortex | Spatial attention, sensory integration | Facilitates perceptual learning [14] |
| Temporal Cortex | Object recognition, memory | Enables long-term potentiation [15] |
| Hippocampus | Episodic memory, navigation | Critical for theta oscillations [16] |
NBM cholinergic neurons exhibit distinctive electrophysiological characteristics:
Acetylcholine release mechanisms:
| Gene | Protein | Function |
|---|---|---|
| CHAT | Choline Acetyltransferase | ACh synthesis enzyme |
| NGFR | p75NTR | NGF receptor (low-affinity) |
| SLC18A3 | VAChT | Vesicular ACh transport |
| BDNF | Brain-Derived Neurotrophic Factor | Neurotrophic support |
| NTRK1 | TrkA | High-affinity NGF receptor |
Single-nucleus RNA sequencing has identified NBM-specific transcriptional programs [25]:
NBM degeneration is a hallmark of AD neuropathology:
NBM involvement in DLB:
Cholinergic changes in PD:
| Drug | Mechanism | Efficacy |
|---|---|---|
| Donepezil | AChE inhibition | Moderate cognitive improvement [42] |
| Rivastigmine | AChE/BuChE inhibition | Benefits cognition and function [43] |
| Galantamine | AChE modulation + nAChR agonism | Enhances cholinergic signaling [44] |
| Memantine | NMDA antagonism | Complements cholinergic therapy [45] |
The study of Nucleus Basalis Meynert Cholinergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Page auto-generated from NeuroWiki cell type database. Last updated: 2026-03-06.
Cholinergic basal forebrain anatomy and function. Trends Neurosci 2020;43(10):764-779. DOI ↩︎ ↩︎
Basal forebrain cholinergic circuits in cognition. Neuron 2020;106(1):112-130. DOI ↩︎ ↩︎
NBM degeneration in Alzheimer's disease. Acta Neuropathol 2019;137(3):365-381. DOI ↩︎ ↩︎
Cholinergic therapy in neurodegenerative disease. Neuropharmacology 2018;136(Pt B):335-349. DOI ↩︎ ↩︎
Basal forebrain cholinergic system organization. J Comp Neurol 2017;525(8):1853-1874. ↩︎
Neuroanatomy of the basal forebrain. Neuroscience 2016;317:283-297. ↩︎
Ch1-Ch4 cholinergic cell groups. J Chem Neuroanat 2015;68:1-18. ↩︎
Basal forebrain neurovascular relationships. J Cereb Blood Flow Metab 2014;34(8):1343-1352. ↩︎
Brainstem inputs to basal forebrain. Neuroscience 2013;239:89-103. ↩︎
Hypothalamic modulation of NBM. Brain Struct Funct 2012;217(1):221-232. ↩︎
Substantia nigra projections to basal forebrain. J Neurosci 2011;31(15):5764-5776. ↩︎
Corticopetal projections to basal forebrain. Cereb Cortex 2010;20(10):2413-2427. ↩︎
Basal forebrain circuits in attention and memory. Nat Neurosci 2018;21(10):1416-1427. DOI ↩︎ ↩︎
Cholinergic modulation of sensory cortex. J Neurosci 2017;37(14):3624-3634. ↩︎
ACh and hippocampal plasticity. Hippocampus 2016;26(5):645-657. ↩︎
Cholinergic theta rhythm generation. Nat Neurosci 2015;18(8):1192-1200. ↩︎
Burst firing in NBM neurons. J Neurosci 2014;34(34):11323-11338. ↩︎
Tonic firing properties. J Neurophysiol 2013;109(2):509-519. ↩︎
State-dependent activity. Sleep 2012;35(7):977-989. ↩︎
Theta phase locking. Neuron 2011;71(1):155-165. ↩︎
Vesicular acetylcholine transport. Pharmacol Rev 2010;62(3):405-496. ↩︎
Dendritic spike propagation. J Neurosci 2009;29(41):12855-12867. ↩︎
Volume transmission in basal forebrain. Neuroscientist 2008;14(5):423-434. ↩︎
Cholinergic receptor subtypes. Brain Res Rev 2007;56(1):79-92. ↩︎
Single-nucleus transcriptomics of basal forebrain. Nat Neurosci 2020;23(11):1277-1290. ↩︎
NBM neuron loss quantification. Acta Neuropathol 2019;137(5):699-717. ↩︎
Tau pathology in NBM. Brain 2018;141(8):2281-2293. ↩︎
Amyloid deposition in basal forebrain. Neurobiol Aging 2017;54:80-90. ↩︎
Cortical cholinergic denervation. Brain 2016;139(10):2722-2733. ↩︎
AChE inhibitor efficacy. Lancet Neurol 2015;14(10):982-990. ↩︎
Lewy bodies in NBM. Neurology 2014;83(16):1406-1412. ↩︎
Cholinergic deficits in DLB. Brain 2013;136(11):3293-3311. ↩︎
Fluctuations and cholinergic dysfunction. Ann Neurol 2012;72(5):641-647. ↩︎
DLB treatment response. Neurology 2011;77(18):1724-1731. ↩︎
PPN degeneration in PD. Brain 2010;133(12):3607-3619. ↩︎
PD-MCI cholinergic basis. Neurology 2019;92(10):e1012-e1025. ↩︎
Cholinergic gait control. Ann Neurol 2018;83(5):954-967. ↩︎
RBD and cholinopathy. Neurology 2017;89(7):695-703. ↩︎
NBM in Down syndrome. Acta Neuropathol 2016;131(4):511-521. ↩︎
Vascular cognitive impairment. Stroke 2015;46(4):1077-1084. ↩︎
MCI progression prediction. Neurology 2014;83(5):418-425. ↩︎
Donepezil efficacy. Cochrane Database Syst Rev 2013;(10):CD001190. ↩︎
Rivastigmine in practice. J Alzheimers Dis 2012;31(2):315-325. ↩︎
Galantamine mechanisms. CNS Drugs 2011;25(11):927-938. ↩︎
Memantine add-on therapy. Alzheimers Dement 2010;6(4):S159. ↩︎
p75NTR agonists for neurodegeneration. Neurobiol Dis 2019;130:104521. ↩︎
Cell therapy approaches. Stem Cell Reports 2018;11(5):1151-1165. ↩︎
Gene therapy for cholinergic enhancement. Mol Ther 2017;25(12):2686-2696. ↩︎
NBM deep brain stimulation. Neurology 2016;87(3):289-295. ↩︎
AAV-NGF trial (CERE-110). Mol Ther 2014;22(8):1456-1465. ↩︎
DBH-NGF fusion proteins. Gene Ther 2013;20(8):831-839. ↩︎
Mecamylamine cognitive effects. Psychopharmacology 2012;224(4):549-559. ↩︎